

Botanical Blockade: Phytochemical Targeting of Nf-Kb in Cancer Therapy

Mohd. Wasiullah¹, Piyush Yadav², Girijesh Yadav^{3,*}, Pritam Kumar Yadav⁴

Abstract

The control of inflammation, corpuscle survival, proliferation, and allowed response are all influenced by the acute archetypal agent NF-κB. Its abnormal activity is typically seen in a range of malignancies, where it aids in bump advancement, metastasis, and treatment waste. The function of NF-κB in scar analysis is discussed in this product, along with significant phytochemicals that seem to be interested in targeting this pathway, based on recent investigation. It also offers details on their workings, areas for improvement, and challenges with logical operation. The intricate signaling networks that play a part in the development and metastasis of cancer have long been the focus of oncology exploration. Among these pathways, nuclear factor- kappa B (NF- κB) is a crucial controller of inflammation, cell survival, and proliferation, making it a promising target for cancer remedy. In recent times, interest has concentrated on the capability of natural composites deduced from shops, known as phytochemicals, to modify NF- κB exertion. This composition explores the eventuality of phytochemicals to target NF- κB for cancer treatment, as well as their mechanisms of action, preclinical effectiveness, clinical uses, challenges, and possible unborn paths in the use of botanical substances to combat cancer.

Keywords: Cancer, NF-κB signaling pathway, anti-cancer activity, Nrf2/NF-κB crosstalk, botanical blockade

INTRODUCTION

The hallmarks of cancer, a convoluted and merged suffering, are amoral corpuscle development, metastasis, and artifice of corpuscle death. One of the many minuscule pathways that are active in cancer is NF-κB, which is essential for immunology, survival, and seditious adaptation. Although NF-κB's activity is tightly controlled in healthy cells, its diligent activation in the presence of widespread malice raises the risk of metastasis, waste to apoptosis, and corpuscle proliferation. NF-κB

dysregulation has made it the main target of corrective intervention. Many of the chemicals that are forming from stores have become potent inhibitors of NF-κB activation because of their added use in typical scar treatment treatments. Honored for their anti-inflammatory, antioxidant, and anti-cancer properties, these phytochemicals provide a fascinating volition to approved treatments, albeit with lower egregious side goods. NF- κB exertion is profoundly regulated by commerce with inhibitory IκB proteins. The cytoplasm of the stylish beef contains NF- κB in the form of an abeyant and abeyant IκB- bound complex. For the NF- κB circuit to serve, the IκB kinase (IKK) circuit must be actuated. IKK is made up of an authoritative unit, IKKγ, and two catalytic units, IKKα and IKKβ. Phosphorylation-

*Author for Correspondence

Girijesh Yadav
 E-mail: girijeshyadav062@gmail.com

¹Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

²Professor & Head, Department of Pharmaceutical Chemistry, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

³Associate Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

⁴Research Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

Received Date: December 14, 2024

Accepted Date: January 04, 2025

Published Date: January 15, 2025

Citation: Mohd. Wasiullah, Piyush Yadav, Girijesh Yadav, Pritam Kumar Yadav. Botanical Blockade: Phytochemical Targeting of Nf-Kb in Cancer Therapy. Research and Reviews: Journal of Pharmacognosy. 2025; 12(1):13–21p.

convinced decline of the I κ B asset by IKK allows for the nuclear (Figure 1) [1, 2].




Figure 1. Steps of cancer progression.

NF- κ B IN BLIGHT BIOLOGY

RelA (p65), RelB, c-Rel, p50, and p52 are bristle members; NF- κ B is an ancestor of archetypal factors. Under normal circumstances, inhibitors of NF- κ B (I κ Bs) keep NF- κ B dimers in the cytoplasm in an abeyant structure. After being activated by a variety of stimuli, including oxidative stress, pro-inflammatory cytokines (TNF, IL-1), and advance factors, NF κ B is moved to the nucleus, where it attaches to DNA sequences to promote the announcement of genes involved in inflammation, survival, proliferation, and metastasis [3].

In cancer, abiding NF- κ B activation contributes to tumorigenesis through several mechanisms:

1. *Corpuscle Adaptation*: NF- κ B induces the announcement of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL) that assure blight beef from programmed corpuscle death.
2. *Deepening*: NF- κ B activates the archetype of pro-inflammatory cytokines (TNF- α , IL-6) that actualize a tumor-supportive microenvironment [4].
3. *Angiogenesis*: NF- κ B regulates the announcement of angiogenic factors like VEGF (vascular endothelial advance factor), and the announcement bumps claret barge formation [5–6].
4. *Alteration*: NF- κ B influences the announcement of genes circuitous in corpuscle adhesion, migration, and invasion, accidental to blight spread.

Due to its cardinal role in cancer, NF- κ B has advised an able ambition for blight therapy. Recent affirmation suggests that phytochemicals – bioactive compounds acquired from plants – can attune this alleyway and action a atypical access to blight treatment.

PHYTOCHEMICALS TARGETING NF- κ B IN BLIGHT THERAPY

Curcumin (Turmeric)

Turmeric's active ingredient, curcumin, has been widely recommended for its anti-cancer qualities. By suppressing upstream signaling molecules like I κ B kinase (IKK), which stops I κ B α from being phosphorylated and abasement, it limits NF- κ B activation. Additionally, curcumin inhibits blight corpuscle admeasurement and induces apoptosis by downregulating the announcement of NF- κ B-dependent genes involved in deepening and corpuscle survival [7].

Epigallocatechin Gallate (EGCG) (Green Tea)

Blooming tea's main polyphenol, EGCG, has been shown to inhibit NF- κ B activity in a variety of cell types. By suppressing IKK activity, it stops the nuclear translocation of NF- κ B. Additionally, EGCG improves the properties of chemotherapy and decreases the release of pro-inflammatory cytokines, making it a useful adjunct in the treatment of blight [8].

Resveratrol (Grapes, Berries)

By blocking IKK activation and shortening the announcement of NF- κ B ambition genes involved in inflammation, survival, and metastasis, resveratrol, a stilbenoid compound that first appears in grapes and other fruits, inhibits NF- κ B. Its anti-cancer properties have been shown to be effective against a variety of cancers, such as lung, breast, and colorectal cancer [9, 10].

Genistein (Soybeans)

Genistein, a flavonoid that begin in soybeans, acts as an NF- κ B inhibitor by modulating assorted signaling pathways. It reduces NF- κ B activation and the announcement of genes accompanying to corpuscle adaptation and proliferation. Genistein has approved almighty anti-cancer furnishings in preclinical studies, decidedly in breast and prostate cancers.

Silymarin (Milk Thistle)

Silymarin, acquired from the milk arrow plant, has been apparent to arrest NF- κ B activation by abbreviation of the phosphorylation of I κ B α . It suppresses the announcement of pro-inflammatory cytokines and enhances apoptosis in blight cells. Silymarin's chemopreventive furnishings are decidedly acclaimed in alarmist cancer.

Berberine (Goldenseal, Others)

Berberine, an alkaloid that begins in several plants, inhibits NF- κ B activation by preventing I κ B degradation. It has apparent anti-cancer furnishings in assorted cancers, including colorectal and alarmist cancer, by inducing corpuscle aeon arrest, apoptosis, and abbreviation inflammation.

Sulforaphane (Cruciferous Vegetables)

Sulforaphane, a bioactive admixture that begins in cruciferous vegetables like broccoli, is an almighty NF- κ B inhibitor. It modulates several signaling pathways, including those circuitous in oxidative accent and inflammation, to block NF- κ B activation. Sulforaphane has been apparent to arrest the advance of blight beef in lung, prostate, and breast blight models.

Table 1. Natural compounds targeting NF- κ B pathway and their mechanisms of action.

Name	Major Source	Mechanism
Gallic acid	<i>Terminalia chebula</i> (Gallnut)	Decreasing the acetylation of RelA.
Genistein	<i>Glycine max</i> (Soybean)	Downregulating NF- κ B expression and the DNA binding and transcriptional activities of NF- κ B.
Macranthoin G	<i>Eucommia ulmoides</i> (Gutta-Percha)	Inhibiting DNA binding of NF- κ B and activating phosphorylation of I κ B.
Obovatol	<i>Magnolia obovate</i> (Whitebark magnolia)	Suppressing NF- κ B translocation to the nucleus as well as I κ B release resulting in the inhibition of the DNA binding activity of NF- κ B.
Terostilbene	<i>Prunus dulcis</i> (Almond)	Hindering the activation of PI3K/Akt/IKK (I κ B kinase).
Quercetin	<i>Brassica oleracea var. italica</i> (Broccoli)	Suppressing I κ B phosphorylation, NF- κ B translocation, and NF- κ B-DNA binding activity.
Salidroside	<i>Rhodiola rosea</i> (Roseroot)	Suppressing phosphorylation of NF- κ B.
Silymarin	<i>Silybum marianum</i> (Milk thistle)	Suppressing NF- κ B-DNA binding activity.

MECHANISMS OF ACTION

Phytochemicals about ambition NF- κ B at several key credibilities in its activation pathway:

- *IKK Circuitous Inhibition*: The IKK complex is blocked by abounding phytochemicals, which stops I κ B α , the inhibitory protein that keeps NF- κ B in the cytoplasm, from being phosphorylated and abasemented [11].
- *Reduction of Pro-inflammatory Cytokines*: Phytochemicals reduce the activation of NF- κ B in the bump microenvironment by preventing the generation of cytokines.
- *Apoptosis Induction*: By blocking NF- κ B-mediated anti-apoptotic proteins, certain polyphenols can accelerate apoptosis in blight meat [12].
- *Blocking I κ B Degradation*: Certain substances stop I κ B proteins from breaking down, which stops NF- κ B from moving into the nucleus.
- *Modulation of NF- κ B Subunits*: Some phytochemicals affect the activity and expression of NF- κ B subunits (such as p65 and p50), which in turn controls the expression of genes downstream.
- *Interference with NF- κ B Target Genes*: NF- κ B target genes (such as COX-2, Bcl-2, and TNF- α) that are involved in angiogenesis, inflammation, and cell survival can have their expression downregulated by phytochemicals (Table 1).

CLINICAL ABEYANT AND CHALLENGES

While preclinical studies on phytochemicals targeting NF- κ B accept apparent able results, there are several challenges that need to be addressed before these compounds can be acclimated as able blight therapies:

- *Bioavailability*: Abounding phytochemicals accept poor bioavailability due to their bound assimilation and accelerated metabolism in the body. Formulation strategies, such as nanoencapsulation or co-administration with bioavailability enhancers, may be bare to advance their effectiveness.
- *Dosage and Toxicity*: The optimal dosage of these compounds in bodies of charcoal is unclear. Although they are advised safe, aerial concentrations may be appropriate for ameliorative effects, which could accession apropos about abeyant toxicity.
- *Analytic validation*: Despite able preclinical data, analytic trials evaluating the adeptness and assurance of these compounds in blight patients are limited. More accurate analytic studies are all-important to authorize their ameliorative abeyant and analyze the best analysis regimens [13–17].

CLINICAL ABEYANT OF PHYTOCHEMICALS IN NF- κ B-TARGETED BLIGHT THERAPY

Current Analytic Trials Utilizing Phytochemicals

When it comes to targeting NF- κ B in blight therapy, phytochemicals are dispatched into the spotlight. Several analytic trials are currently underway to analyze the abeyant of these accustomed compounds in alleviative assorted types of cancer. From resveratrol in grapes to curcumin in turmeric, advisers are diving into the apple of plant-based anesthetic to alleviate new possibilities in blight treatment.

Potential Applications and Challenges in Analytic Settings

While the analytic abeyant of phytochemicals in targeting NF- κ B is promising, there are challenges that need to be addressed. From standardizing dosages to compassionate interactions with accepted treatments, amalgamating these accustomed compounds into analytic settings requires accurate consideration. However, the abeyant applications of phytochemicals in acceptable the capability of blight analysis make the adventure worthwhile.

CHALLENGES AND APPROACHING DIRECTIONS IN UTILIZING PHYTOCHEMICALS FOR NF- κ B INHIBITION

Overcoming Bioavailability and Pharmacokinetic Challenges

One of the key challenges in utilizing phytochemicals for NF- κ B inhibition is their bioavailability and pharmacokinetics. These compounds generally face hurdles in extensive their ambition in acceptable quantities due to poor assimilation or accelerated metabolism. Advisers are exploring avant-garde commitment systems and formulations to enhance the bioavailability of phytochemicals and aerate their ameliorative effects.

Combination Therapies and Alone Approaches

Moving forward, the approach of utilizing phytochemicals for NF- κ B inhibition lies in aggregate therapies and alone approaches. By amalgam these accustomed compounds with accepted treatments or dressmaking their use to alone accommodating profiles, advisers aim to optimize outcomes and abbreviate ancillary effects. Embracing holistic and alone access holds the key to unlocking the abounding abeyant of phytochemicals in blight therapy.

THE ROLE OF NRF2 IN THE CANCER ENVIRONMENT

Its capital action to detoxify the corpuscle environment is the source of the circuitous agreement between this gene and blight; its adjustment and accentuation have been described as a “double-edged sword” with various complexities. Blight development and resistance are advanced by Nrf2 overexpression brought on by Nrf2 accouterment mutations (e.g., genuine mutations in Keap1, Nrf2, or Cul3; epigenetic DNA methylation of Keap1, etc.) or Nrf2/Keap1 post-translational modifications. The detrimental effects of radiation and chemotherapy can, in fact, cause Nrf2 baseline activation to progress to metabolic reprogramming for corpuscle growth, as well as to an antioxidant and detoxifying activity.

Nrf2 inhibitors are desired in certain types of malignancies, however, there are currently no FDA-approved medications available. Furthermore, one should stay away from Nrf2 inducers. However, Nrf2 may be initially inhibited in certain cancer types, as demonstrated in the prostate tumors of transgenic adenocarcinoma of abrasion prostate (TRAMP) mice and in a model of the stepwise animal mesenchymal axis corpuscle (MSC) arch-to-bump advancement and lower adaption rates. The Nrf2 abolishment in TRAMP mice was found to be caused by hypermethylation of the Nrf2 promoter. In addition to the modified announcement of Nrf2, this archetypal agency is essential for persistent inflammation, which initiates the development of blight.

In this situation, Nrf2 can suppress proinflammatory gene activation and override the announcement of cytoprotective proteins like HO-1 and SOD. Inducers of Nrf2 may play a chemopreventive effect in the latter two diseases. Oxidable diphenols, which are horribly enriched in vegetable matrices, are one of the recognized inducers. Because they change into the matching quinones under oxidative accent circumstances, the living isomers are specifically ortho- and para diphenols. By peacefully attaching to Keap1 thiol groups, these aftermost can properly activate Nrf2.

Phlorizin and ursolic acid, two non-diphenol angel components, demonstrated an effect that appeared on Nrf2. The glucoside obtained from the dihydrochalcone phloretin is called phlorizin. The alternation apparatus between the archetypal agency and the polyphenol was not approved, even though both in vitro and in vivo research accurately demonstrated its fascination in Nrf2 activation. Van der Waals, arctic, and hydrogen bond interactions are examples of non-covalent interactions that are appropriated by molecular advancing simulations. Ursolic acid also activates Nrf2, but by a different mechanism: Kim et al. confirmed that it reduces Nrf2 apostle methylation by blocking the function of histone deacetylases (HDACs) and DNA methyltransferases (DNMTs).

IN VIVO STUDIES OF ANTICANCER HERBAL MEDICINE

The herbal remedies are both in vivo and in vitro activated. In vivo, the use of the various alleviative herbs has activated their anticancer properties in altered animal models. Numerous

investigations on in vivo abstracts of the prevalent modified anticancer plants in mouse models are available. For example, in tumor-bearing animals, dihydroartemisinin appeared to inhibit interleukin 4 (IL-4), halt bump tissue, and access the analog of interferon-gamma (IFN- γ). In a similar vein, artesunate, a derivative of artemisinin, also seems to be a powerful biologic that inhibits the growth of angiogenic Kaposi's sarcoma, advances the suppression of A549 and H1299 lung tumors by a dose of 100 mg/kg, eliminates animal prostate blight xenograft, and inhibits the progression of leukemia in mice (Figure 2).




Figure 2. In vivo studies of anti-cancer medicine.

An annual dose of 2 mg/kg of radiation was administered to C57BL/6 mice, which was accepted to be able to affix lung cancer. Berberine's ability was restored when it was acclimated in combination with other substances. By inhibiting bump progression and shortening blight metastasis, coptisine, an alkaloid of *Coptidis rhizoma*, is recognized to accept anticancer furnishings back acclimated at concentrations of 150 mg/kg adjacent to BALB/c nude mice. The RAS-ERK pathway inhibition was a suitable mechanism for this action. By using the aqueous abstract of *H. diffusa*, which inhibits beef admeasurement in a dose-dependent manner, delays S appearance, and arrests beef in the G0/G1 phase, addition abstraction was also carried out on the nude mice on HepG2 beef.

Similarly, crude bump nude mice were used to test SBT-A's aerial anticancer effect. Using the 95-D Xenograft model, Yang et al. demonstrate the anticancer properties of the polysaccharides removed from *S. barbata*. The results demonstrated that polysaccharides close to a 95-D corpuscle line have observable anti-proliferative effects. The declaration of phospho-c-Met and other signaling components, such as phospho-Akt and phospho-Erk, is also discussed. Using a 95-D subcutaneous xenograft model, in vivo abstraction also showed the highest anticancer effect. Following three weeks of a single circadian intraperitoneal bang, the bump advance was significantly reduced at 100 and 200 mg/kg dosages (47.72% and 13.6%, respectively). Additionally, the ex vivo investigations demonstrated that *S. barbata* polysaccharides inhibit the phosphorylation of the c-Met signaling pathway.

Additionally, Li et al. abandoned a steroidal saponin from *P. polyphylla* that caused apoptosis in A549 cells and prevented bump advancement in Lewis-bearing C57BL/6 mice. Effects included a significant increase in thymus and beddy-bye indices, a decrease in anarchic cytokines (TNF- α , IL-8, and IL-10), and a cogent inhibition amount of $26.49 \pm 17.30\%$, $40.32 \pm 18.91\%$, and $54.94 \pm 16.48\%$ for steroidal saponin in the absorption of 2.5, 5.0, and 7.5 mg/kg. Due to the weight of the tumor and the bargain aggregate, this in turn prevented the advancement of the bump in C57BL/6 mice. When 0.25, 0.50, and 0.75 mg/mL of steroidal saponin are absorbed by A549 beef, it causes nuclear alterations, DNA condensation, chromatin breakage, and apoptosis. Steroid saponin-inhibited bump progress was linked to apoptotic consecration, anarchic response, and a reduction in ROS.

Additionally, Wanga et al. show the effects of *P. frutescens* isoegomaketone on tumor-xenograft nude mice and Huh-7 hepatoma corpuscle blight. Isoegomaketone inhibited meat and reduced bump weight and volume, according to the aftereffects. When 10 nM/L of isoegomaketone was absorbed, it first reduced pAkt and then had an impact on Akt. Isoegomaketone from *P. frutescens* inhibited the advancement of hepatoma corpuscle blight bumps by disrupting the PI3K/Akt signaling pathway. Additionally, by inhibiting cyclooxygenase 2 activity, *R. coptidis* demonstrated anticancer efficacy in rats as appropriate. After *R. coptidis* extracts were administered, the frequency of aberrant catacomb foci in the rat colon dropped by 54%.

Manjamalai and Grace appear the apoptosis forth with blurred angiogenesis and lung alteration activities of the capital oils of *W. chinensis* by application of B16F-10 melanoma corpuscle band in C57BL/6 mice. The mice were injected with B16F-10 melanoma beef through the appendage attitude and advised with altered doses of capital oil. A 50- μ g capital oil absorption showed the best cytotoxic activities with 65.17% accident aural 24 h. Compared to the ascendancy group, the initial samples had more apoptotic meat added abounding times. Additionally, they found that samples treated with capital oil had higher amounts of critical proteins including p53 and caspase-3 than did additional non-treated samples. They suggested this bulb for cancer analysis and progression.

Oridonin from *R. rubescens* shown potent anticancer abeyant properties in the gallbladder during in vivo activities. When given intraperitoneally to athymic nude mice for three weeks at an absorption rate of 5, 10, and 15 mg/kg, oridonin significantly slowed the formation of NOZ xenografts. Additionally, oridonin enhanced the Bax/Bcl-2 ratio, reduced NF- κ B nuclear translocation, and activated caspase-3, caspase-9, and PARP-1, indicating that the mitochondrial alleyway is worried about oridonin-advised apoptosis.

In comparison to the ascendancy adjacent MTLn3 breast cancers in rats, studies have shown that the monomer dihydroartemisinin (DHA) and two artemisinin dimers, dimer-hydrazone (dimer-Sal) and dimer-alcohol (dimer-OH), have anticancer properties. In contrast to the ascendant group, dimer-Sal, dimer-OH, and DHA appeared to significantly inhibit tumors in mice because of the abstraction. Furthermore, it was empirically demonstrated that the dimers were added far more frequently than the monomers.

Additionally, it seems that artemisinin can prevent breast blight in rats when given a specific articulate dosage of 7, 12-dimethylbenz anthracene (DMBA) at 50 mg/kg. This dosage is known to quickly inhibit many breast cancers. Both groups of starting rats were observed for breast cancers for 40 weeks following the administration of DMBA with 0–2% artemisinin to the ambition accumulation and apparent aliment in delicate anatomy to the ascendancy group. Compared to ascendancy feeding (96%), articulate artemisinin significantly reduces the development of breast cancers (57%). With the acceptance of lower ancillary furnishings, the research suggests that artemisinin has the potential to be a powerful blight chemoprevention agent [168]. In a similar vein, giving rats curcumin reduced their glycoprotein (Gp A72) by 73%, which correspondingly reduced paw inflammation.

Tanaka et al. investigated the effects of bake-apple extracts of *G. indica* on colonic aberrant catacomb foci caused by azoxymethane (AOM) in masculine typical rats (F344). They start by decreasing the nuclear antigen basis of proliferating corpuscles and the aerial concentrations of quinone reductase and glutathione S-transferase. They also demonstrate the most effective chemopreventive effects of garcinol.

CHALLENGES AND FUTURE DIRECTIONS

Although targeting NF- κ B with phytochemicals in blight study shows promise, there are several obstacles to overcome:

- *Bioavailability*: A lot of phytochemicals have low bioavailability, which limits their analytical

potential. Their ameliorative potential could be advanced by creating further bioavailable formulations or accumulating phytochemicals with adjuvants to improve assimilation.

- *Dosage Optimization*: Finding the ideal phytochemical dosage for NF-κB inhibition is crucial since excessive dosages may cause negative effects or interfere with normally permitted function.

CONCLUSION: HARNESSING BOTANICAL COMPOUNDS FOR CANCER TREATMENT

In blight therapy, botanical barricade, which targets NF-κB, is a sensitive access. Curcumin, EGCG, resveratrol, and other phytochemicals have been shown to have the ability to modulate NF-κB signaling and have anti-cancer properties. A safer alternative with fewer auxiliary effects may be made possible by these substances, which operate as an adjuvant for accessory furnishings with recognized medicines. To understand their abundant remedial potential, however, issues related to bioavailability, dosage, and analytical validation must be resolved. Future research into these phytochemicals' atomic mechanisms as well as analytical studies will be crucial in determining how well they treat blight. All these findings support the ability of apple phytochemicals to maintain the physiological equilibrium between the two main actors of oxidative and inflammatory cell status, preventing and hindering the degradation of cell conditions that usually lead to the emergence of different types of cancer. These byproducts also have considerable bioactivities and should be given more consideration in the manufacturing of nutraceuticals, as evidenced by the fact that a large majority of the research under review used substances obtained from the waste of the apple supply chain. The main mechanism affecting apples' bioactivity on the transcription factors Nrf2 and NF-κB, whose imbalance is directly connected to the onset and spread of various cancers, maybe their high concentration of mild electrophilic compounds.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492.
2. Singh P, Mazumdar P, Harikrishna JA. et al. Sheath blight of rice: a review and identification of priorities for future research. *Planta*. 2019;250:1387–1407. doi:10.1007/s00425-019-03246-8.
3. Walters DR, Avrova A, Bingham IJ, et al. Control of foliar diseases in barley: towards an integrated approach. *Eur J Plant Pathol*. 2012;133:33–73. doi:10.1007/s10658-012-9948-x.
4. Cheng H. *Advanced Textbook on Traditional Chinese Anesthetic and Pharmacology*. Beijing, China: New World Press; 1995.
5. Shehab NG, Mahdy A, Khan SA, Nouredin SM. Chemical constituents and biological activities of *Fagonia indica* Burm F. *Res J Med Plant*. 2011;5:531–546.
6. Faried A, Kurnia D, Faried L, Usman N, Miyazaki T, Kato H, Kuwano H. Anticancer effects of gallic acid isolated from Indonesian herbal medicine, *Phaleria macrocarpa* (Scheff.) Boerl, on human cancer cell lines *Int J Oncol*. 2007;30:605–613. doi:10.3892/ijo.30.3.605.
7. Sohi KK, Mittal N, Hundal MK, Khanduja KL. Gallic acid, an antioxidant, exhibits antiapoptotic abeyant in accustomed animal lymphocytes: A Bcl-2 absolute mechanism. *J Nutr Sci Vitaminol*. (Tokyo). 2003;49(4):221–227. doi:10.3177/jnsv.49.221
8. Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y, Yabu Y. Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. *Biochem Biophys Res Commun*. 1994;204(2):898–904.
9. Sun J, Chu YF, Wu X, Liu RH. Antioxidant and antiproliferative activities of common fruits. *J Agric Food Chem*. 2002;50(25):7449–7454.
10. Taraphdar AK, Roy M, Bhattacharya RK. Natural products as inducers of apoptosis: Implication for cancer therapy and prevention. *Cur Science*. 2001:1387–1396.
11. Pal SK, Shukla Y. Herbal medicine: Current cachet and the future. *Asian Pac J Cancer Prev*. 2003;4:281–288.

12. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. *Nat Rev Drug Discov.* 2005;4(3):206–220. doi:10.1038/nrd1657.
13. Saklani A, Kutty SK. Plant-derived compounds in clinical trials. *Drug Discov Today.* 2008;13(3-4):161–171. doi:10.1016/j.drudis.2007.10.010.
14. Wang CZ, Calway T, Yuan CS. Herbal medicines as adjuvants for cancer therapeutics. *Am J Chin Med.* 2012;40(4):657–669. doi:10.1142/S0192415X12500498.
15. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterol.* 2004;127(5 Suppl 1):S35–S50. doi:10.1053/j.gastro.2004.09.014.
16. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. *Cell.* 1986;47(6):921–928. doi:10.1016/0092-8674(86)90807-x.
17. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. *Cell.* 1988;53(2):211–217. doi:10.1016/0092-8674(88)90382-0.